Halozyme: 'Accidental' Business Model Has Exciting Upside Opportunities In 2025
Halozyme provides subcutaneous drug delivery solutions, with several major new products recently approved. Click here to find ...
Halozyme Reiterates 2024 Financial Guidance and Raises 2025 and Multi-Year Financial Guidance
Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company") today provided a financial update, reiterating full ...
Halozyme Announces argenx's VYDURA with ENHANZE® was Granted Regulatory Approval in Japan for Chronic Inflammatory Demyelinating Polyneuropathy
Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that argenx's VYVDURA (efgartigimod alfa and ...
Halozyme’s Strategic Growth and Financial Strength Boosts Buy Rating
Analyst Jason Butler of JMP Securities reiterated a Buy rating on Halozyme (HALO – Research Report), retaining the price target of $73.00.Stay ...
Halozyme announces Vyvdura co-formulated with Enhanze granted MHLW approval
Halozyme announced that Argenx’s Vyvdura, which is co-formulated with Halozyme’s Enhanze drug delivery technology, was granted regulatory approval by Japan’s Ministry of Hea ...
Halozyme raises 2025 guidance, announces $250M stock buyback
Halozyme (NASDAQ:HALO) has raised its financial guidance estimates for 2025 based on expected strong sales of products ...
Mena FN10d
Halozyme Announces Argenx's VYDURA With ENHANZE® Was Granted Regulatory Approval In Japan For Chronic Inflammatory Demyelinating Polyneuropathy
"We are pleased that VYVDURA, with our innovative ENHANZE drug delivery technology, is now approved for two indications in Japan, enabling greater flexibility and optionality for generalized ...
Contract Pharma9d
FDA Approves BMS’ Opdivo Qvantig with Halozyme’s ENHANZE Technology
Becomes the first subcutaneously administered PD-1 inhibitor.
Medindia9d
Halozyme Announces argenx's VYDURA with ENHANZE® was Granted Regulatory Approval in Japan for Chronic Inflammatory Demyelinating Polyneuropathy
SAN DIEGO, Dec. 30, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that argenx's VYVDURA (efgartigimod alfa and hyaluronidase-qvfc), which is co ...